HC Wainwright reiterated their buy rating on shares of Cidara Therapeutics (NASDAQ:CDTX - Free Report) in a research report released on Tuesday, Benzinga reports. The brokerage currently has a $24.00 price target on the biotechnology company's stock.
Several other equities analysts have also commented on the stock. StockNews.com upgraded shares of Cidara Therapeutics from a "sell" rating to a "hold" rating in a report on Friday, September 13th. Needham & Company LLC reiterated a "buy" rating and set a $25.00 target price on shares of Cidara Therapeutics in a report on Wednesday, August 14th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Cidara Therapeutics in a report on Wednesday, August 14th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $29.67.
Get Our Latest Research Report on Cidara Therapeutics
Cidara Therapeutics Stock Up 1.4 %
NASDAQ:CDTX traded up $0.16 on Tuesday, hitting $11.38. The stock had a trading volume of 3,019 shares, compared to its average volume of 39,761. The stock has a market cap of $51.92 million, a price-to-earnings ratio of -1.46 and a beta of 1.03. The company has a fifty day moving average price of $11.58 and a two-hundred day moving average price of $12.36. Cidara Therapeutics has a 1-year low of $10.00 and a 1-year high of $24.40.
Cidara Therapeutics (NASDAQ:CDTX - Get Free Report) last posted its earnings results on Tuesday, August 13th. The biotechnology company reported ($2.05) earnings per share for the quarter, beating the consensus estimate of ($3.94) by $1.89. Cidara Therapeutics had a negative net margin of 289.05% and a negative return on equity of 109.89%. The company had revenue of $0.30 million for the quarter. As a group, analysts anticipate that Cidara Therapeutics will post -12.06 earnings per share for the current year.
Institutional Trading of Cidara Therapeutics
A hedge fund recently raised its stake in Cidara Therapeutics stock. Tocqueville Asset Management L.P. lifted its stake in Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) by 71.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 163,000 shares of the biotechnology company's stock after purchasing an additional 68,000 shares during the period. Tocqueville Asset Management L.P. owned approximately 3.57% of Cidara Therapeutics worth $150,000 as of its most recent SEC filing. Institutional investors own 35.82% of the company's stock.
About Cidara Therapeutics
(
Get Free Report)
Cidara Therapeutics, Inc, a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.
See Also
Before you consider Cidara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cidara Therapeutics wasn't on the list.
While Cidara Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
